Literature DB >> 11684848

Neuroendocrine differentiation and short-term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression.

J Köllermann1, B Helpap.   

Abstract

OBJECTIVES: Neuroendocrine (NE) differentiation in prostate cancer is believed by some authors to play an important role in the development of androgen resistance. However, there is little knowledge about the impact of short-term neoadjuvant hormonal therapy on NE differentiation and on whether the degree of tumor regression is linked with the extent of NE differentiation.
METHODS: NE cells were detected by immunohistochemistry using a chromogranin A antibody. The densities of NE cells in 20 pretreated and 20 nonpretreated radical prostatectomy specimens were compared. Furthermore, we compared the NE cell density in tumors with variable degrees of regression.
RESULTS: The median percentage of tumor cells showing NE differentiation did not significantly differ between pretreated and nonpretreated specimens (0.61%, range 0.0-2.4%, vs. 1.47%, range 0.0-6.8%; p = 0.9896). Twelve nonregressive/slightly regressive tumor foci and 12 strongly regressive tumor foci were assessed. The NE cell density did not differ significantly (p = 0.1227).
CONCLUSIONS: Short-term neoadjuvant hormonal therapy does not induce relevant clonal propagation of NE cells. The degree of tumor regression following short-term neoadjuvant hormonal therapy does not correlate with the extent of NE differentiation.

Entities:  

Mesh:

Year:  2001        PMID: 11684848     DOI: 10.1159/000049792

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  2 in total

1.  [Therapy induced regressive changes of prostate cancer].

Authors:  B Helpap; J Köllermann
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

2.  Review of small cell carcinomas of the prostate.

Authors:  P Furtado; M V A Lima; C Nogueira; M Franco; F Tavora
Journal:  Prostate Cancer       Date:  2011-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.